尿路上皮癌中的检查点抑制剂:未来方向与生物标志物选择
本综述检索PubMed、Web of Science、EMBASE及会议摘要,纳入21项前瞻性试验(12项2期、9项3期),评估检查点抑制剂在转移性尿路上皮癌、肌层浸润性尿路上皮癌及非肌层浸润性膀胱癌中的疗效与毒性,并探讨生物标志物选择。
要点
- 一线转移性尿路上皮癌中,化疗同步检查点抑制剂未显示优效性。
- 诱导化疗后疾病稳定或缓解者,阿维鲁单抗换药维持治疗改善总生存和无进展生存,已确立为一线转移性尿路上皮癌的当前标准治疗。
- 围手术期检查点抑制剂仅限于高危病理分期肌层浸润性尿路上皮癌根治术后纳武利尤单抗辅助治疗。
核心结论
- 检查点抑制剂在尿路上皮癌多个疾病状态中已确立作用,未来应用可能进一步扩大。
- 多种联合方案正在评估中,预测性生物标志物的开发与验证可能有助于识别最可能应答的患者。
- 患者摘要指出,检查点抑制剂在尿路上皮癌中具有广泛活性,联合方案的最佳应用及患者选择仍需进一步研究。
研究设计与样本
- 本综述检索PubMed、Web of Science、EMBASE数据库及会议摘要,纳入评估检查点抑制剂治疗尿路上皮癌的前瞻性试验。
- 共纳入21项试验,包括12项2期试验和9项3期试验,其中转移性尿路上皮癌7项、肌层浸润性尿路上皮癌9项、非肌层浸润性膀胱癌5项。
- 主要终点包括总生存、无复发生存和毒性(当可获得时),次要分析包括应答的生物标志物评估。
主要发现
- 一线转移性尿路上皮癌中,化疗同步检查点抑制剂未能显示优效性。
- 诱导全身化疗后达到疾病稳定或缓解的患者,阿维鲁单抗换药维持治疗改善总生存和无进展生存,已确立为一线转移性尿路上皮癌的当前标准治疗。
- 单药检查点抑制剂是無法耐受化疗患者的一种考虑。
- 围手术期检查点抑制剂仅限于基于病理分期复发风险较高的肌层浸润性尿路上皮癌患者根治术后纳武利尤单抗辅助治疗。
- 美国食品药品监督管理局仅批准帕博利珠单抗用于不适合或拒绝根治性膀胱切除术、对卡介苗(BCG)无应答的原位癌患者。
临床怎么用
- 一线转移性尿路上皮癌:诱导化疗后疾病稳定或缓解者,阿维鲁单抗换药维持治疗为当前标准治疗。
- 无法耐受化疗的转移性尿路上皮癌患者,可考虑单药检查点抑制剂。
- 复发风险较高的肌层浸润性尿路上皮癌患者,根治术后可接受纳武利尤单抗辅助治疗。
- 不适合或拒绝根治性膀胱切除术、对卡介苗无应答的原位癌患者,帕博利珠单抗获美国食品药品监督管理局批准。
- 检查点抑制剂与多种免疫调节剂、抗体药物偶联物、靶向治疗、抗血管生成药物、化疗和放疗联合的试验正在入组患者,可能塑造尿路上皮癌的未来治疗。
局限性
- 患者摘要指出,检查点抑制剂在尿路上皮癌中联合方案的最佳应用及患者选择仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Several recent phase 2 and 3 trials have evaluated the efficacy and toxicity of checkpoint inhibitor (CPI) therapy for urothelial carcinoma (UC) in the metastatic, localized muscle-invasive UC (MIUC), upper tract UC, and non-muscle-invasive bladder cancer (NMIBC) disease state. OBJECTIVE: To assess the outcomes and toxicity of CPIs across the treatment landscape of UC and contextualize their application to current real-world treatment. EVIDENCE ACQUISITION: We queried PubMed, Web of Science, and EMBASE databases and conference abstracts to identify prospective trials examining CPIs in UC. The primary endpoints included overall survival, recurrence-free survival, and toxicity (when available). A secondary analysis included biomarker evaluation of response. EVIDENCE SYNTHESIS: We identified 21 trials, 12 phase 2 and nine phase 3 trials, in which a CPI was used for metastatic UC (seven), MIUC (nine), and NMIBC (five). For first-line (1L) metastatic UC, concurrent chemotherapy with CPIs failed to show superiority. Improved overall and progression-free survival for switch maintenance avelumab (after achieving stable disease or response with induction systemic chemotherapy) has established the current standard of care for 1L metastatic UC. A single-agent CPI is a consideration for patients unable to tolerate chemotherapy. CPIs in the perioperative setting are limited to only the adjuvant treatment with nivolumab after radical surgery for MIUC in patients at a higher risk of recurrence based on pathologic stage. Only pembrolizumab is approved by the Food and Drug Administration for carcinoma in situ unresponsive to bacillus Calmette-Guérin (BCG) in patients who are not fit for or who refuse radical cystectomy. Trials investigating CPIs in combination with multiple immune regulators, antibody drug conjugates, targeted therapies, antiangiogenic agents, chemotherapy, and radiotherapy are enrolling patients and may shape the future treatment of patients with UC. CONCLUSIONS: CPIs have an established role across multiple states of UC, with broadened applications likely to occur in the future. Several combinations are being evaluated, while the development of predictive biomarkers and their validation may help identify patients who are most likely to respond. PATIENT SUMMARY: Our findings highlight the broad activity of checkpoint inhibitors in urothelial carcinoma, noting the need for further investigation for the best application of combinations and patient selection to patient care.
引用
- Meeks JJ, Black PC, Galsky M, et al. Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection. Eur Urol. 2023. PMID: 37258363. doi:10.1016/j.eururo.2023.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。